Multiple Myeloma Research Consortium Announces Data Presentations at the 2011 ASCO Annual Meeting

2011 ASCO Annual Meeting

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced the presentation of studies sponsored by industry partners, Onyx Pharmaceuticals, Bristol-Myers Squibb, Abbott, and Novartis Pharmaceuticals Corporation, and conducted in collaboration with MMRC, at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

A total of five (5) presentations will be made at the ASCO Annual Meeting involving collaborations with MMRC to investigate potential treatments for multiple myeloma.

"We are proud of the work being done by the academic research centers and industry partners that the MMRC works with to accelerate the development of new treatment options for patients with multiple myeloma," said Louise M. Perkins, Chief Scientific Officer, MMRC. "The number and quality of abstracts being presented at this year's ASCO meeting demonstrate the impact of the collaborative efforts underway and showcase a promising pipeline of potential new therapies for multiple myeloma, including carfilzomib, elotuzumab, and panobinostat."

Presentations of data from trials conducted within the MMRC:

 Sunday, June 5; Oral Abstract Session: Myeloma; 9:30 am - 12:30 pm, E354a

Bristol-Myers Squibb/Abbott
Abstract #8014: Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study

 Saturday, June 4, 2011; Poster Discussion Session: Lymphoma and Plasma Cell Disorders; 8:00 am - 12:00 pm, E450b

Onyx Pharmaceuticals
Abstract #8026: The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naïve relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study

Onyx Pharmaceuticals
Abstract #8027: PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis

 Monday, June 6; General Poster Session: Lymphoma and Plasma Cell Disorders; 1:00 pm - 5:00 pm, Hall A

Novartis
Abstract #8075: A Phase Ib study of oral panobinostat in combination with bortezomib in patients with relapsed and refractory multiple myeloma

Bristol-Myers Squibb/Abbott
Abstract #8076: Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States were estimated to be diagnosed with multiple myeloma and approximately 11,000 people died from the disease.

About the Multiple Myeloma Research Foundation (MMRF)

Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $165 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor's investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.

About the Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions. Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas in genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.